DUAL II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide (IDegLira) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin.

Pei Y, Agner BR, Luo B, Dong X, Li D, Liu J, Liu L, Liu M, Lu Y, Nishida T, Xu X, Mu Y

Diabetes, obesity & metabolism31 Aug 2021Cited by 23 (Europe PMC)

PMID34387411PMCIDPMC9291809DOI10.1111/dom.14522PepBankPUB-34387411

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In Chinese adults with type 2 diabetes on basal insulin, IDegLira lowered HbA1c more than insulin degludec alone at week 26.
In plain wordsIn Chinese adults with type 2 diabetes on basal insulin, insulin degludec/liraglutide lowered HbA1c more than insulin degludec alone.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change at week 26
Study
n = 453
Comparator
Insulin degludec
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
IDegLira max. 50 U degludec/1.8 mg liraglutide · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−1.9%
IDegLira
HbA1c change
−1%
degludec
Estimated treatment difference
−0.92%
IDegLira versus degludec
Source sentences
Summary
Superiority was confirmed for IDegLira over degludec in HbA1c change (-1.9% vs. -1.0%, respectively, estimated treatment difference [ETD] [95% confidence interval]: -0.92% [-1.09; -0.75], P < .0001)
1 context sentence(design, population, supporting numbers)
Summary · context
In DUAL II China, a randomized, double-blinded, multicentre, treat-to-target trial, Chinese adults with T2D and HbA1c of 7.5% or more on basal insulin and metformin, with or without other oral antidiabetic drugs (OADs), were randomized 2:1 to 26 weeks of treatment with either IDegLira (max. dose 50…
Report a problemFND-3438741101
02HumanRandomized controlled trialEfficacy outcome
In Chinese adults with type 2 diabetes on basal insulin, IDegLira gave a lower body weight change than insulin degludec alone at week 26.
In plain wordsIn Chinese adults with type 2 diabetes on basal insulin, weight fell slightly with insulin degludec/liraglutide and rose slightly with insulin degludec alone.
Peptide
Liraglutide
Outcome
DecreaseBody weight change at week 26
Study
n = 453
Comparator
Insulin degludec
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
IDegLira max. 50 U degludec/1.8 mg liraglutide · 26 weeksAs given in this study (human).
Measurements
Body weight change
−0.7 kg
IDegLira
Body weight change
0.4 kg
degludec
Estimated treatment difference
−1.08 kg
IDegLira versus degludec
Source sentences
Summary
body weight change (-0.7 vs. +0.4 kg, respectively, ETD [95% CI]: -1.08 kg [-1.63; -0.52], P = .0002)
1 context sentence(design, population, supporting numbers)
Summary · context
In DUAL II China, a randomized, double-blinded, multicentre, treat-to-target trial, Chinese adults with T2D and HbA1c of 7.5% or more on basal insulin and metformin, with or without other oral antidiabetic drugs (OADs), were randomized 2:1 to 26 weeks of treatment with either IDegLira (max. dose 50…
Report a problemFND-3438741102
03HumanRandomized controlled trialSafety outcome
In Chinese adults with type 2 diabetes on basal insulin, IDegLira had a lower rate of severe or blood glucose-confirmed hypoglycaemia than insulin degludec alone.
In plain wordsIn Chinese adults with type 2 diabetes on basal insulin, insulin degludec/liraglutide caused fewer low blood sugar episodes than insulin degludec alone.
Peptide
Liraglutide
Outcome
DecreaseSevere or blood glucose-confirmed hypoglycaemia
Study
n = 453
Comparator
Insulin degludec
Analysis
Secondary
Outcome group
Adverse events · Metabolic and weight
Studied dose
IDegLira max. 50 U degludec/1.8 mg liraglutide · 26 weeksAs given in this study (human).
Measurements
Estimated rate ratio
0.53
IDegLira versus degludec
Source sentences
Summary
severe or BG-confirmed hypoglycaemia (estimated rate ratio [95% CI]: 0.53 [0.30; 0.94], P = .0297)
1 context sentence(design, population, supporting numbers)
Summary · context
In DUAL II China, a randomized, double-blinded, multicentre, treat-to-target trial, Chinese adults with T2D and HbA1c of 7.5% or more on basal insulin and metformin, with or without other oral antidiabetic drugs (OADs), were randomized 2:1 to 26 weeks of treatment with either IDegLira (max. dose 50…
Report a problemFND-3438741103
04HumanRandomized controlled trialEfficacy outcome
In Chinese adults with type 2 diabetes on basal insulin, the odds of reaching HbA1c below 7.0% without hypoglycaemia and/or weight gain were greater with IDegLira than with insulin degludec alone.
In plain wordsIn Chinese adults with type 2 diabetes, insulin degludec/liraglutide gave better odds of HbA1c under 7.0% without low blood sugar or weight gain than degludec.
Peptide
Liraglutide
Outcome
IncreaseHbA1c below 7.0% without hypoglycaemia and/or weight gain
Study
n = 453
Comparator
Insulin degludec
Outcome group
Glycemic control · Metabolic and weight
Studied dose
IDegLira max. 50 U degludec/1.8 mg liraglutide · 26 weeksAs given in this study (human).
Measurements
HbA1c target
< 7%
responder criterion
Source sentences
Summary
The odds of achieving HbA1c less than 7.0% without hypoglycaemia and/or weight gain were greater with IDegLira than degludec (P < .0001 for all).
1 context sentence(design, population, supporting numbers)
Summary · context
In DUAL II China, a randomized, double-blinded, multicentre, treat-to-target trial, Chinese adults with T2D and HbA1c of 7.5% or more on basal insulin and metformin, with or without other oral antidiabetic drugs (OADs), were randomized 2:1 to 26 weeks of treatment with either IDegLira (max. dose 50…
Report a problemFND-3438741104
05HumanRandomized controlled trialEfficacy outcome
In Chinese adults with type 2 diabetes on basal insulin, the daily insulin dose at week 26 was lower with IDegLira than with insulin degludec alone.
In plain wordsIn Chinese adults with type 2 diabetes on basal insulin, people on insulin degludec/liraglutide needed a lower daily insulin dose than those on degludec alone.
Peptide
Liraglutide
Outcome
DecreaseDaily insulin dose at week 26
Study
n = 453
Comparator
Insulin degludec
Outcome group
Glycemic control · Metabolic and weight
Studied dose
IDegLira max. 50 U degludec/1.8 mg liraglutide · 26 weeksAs given in this study (human).
Measurements
Daily insulin dose
34.3 U
IDegLira
Daily insulin dose
37.4 U
degludec
Source sentences
Summary
Daily insulin dose at 26 weeks was lower for IDegLira (34.3 U) than degludec (37.4 U) (P = .0014).
1 context sentence(design, population, supporting numbers)
Summary · context
In DUAL II China, a randomized, double-blinded, multicentre, treat-to-target trial, Chinese adults with T2D and HbA1c of 7.5% or more on basal insulin and metformin, with or without other oral antidiabetic drugs (OADs), were randomized 2:1 to 26 weeks of treatment with either IDegLira (max. dose 50…
Report a problemFND-3438741105
06HumanRandomized controlled trialSafety outcome
In Chinese adults with type 2 diabetes on basal insulin, no unexpected safety signals were observed with IDegLira over 26 weeks.
In plain wordsIn Chinese adults with type 2 diabetes on basal insulin, no unexpected safety problems were seen with insulin degludec/liraglutide.
Peptide
Liraglutide
Outcome
No significant changeUnexpected safety signals
Study
n = 453
Comparator
Insulin degludec
Outcome group
Adverse events · Metabolic and weight
Studied dose
IDegLira max. 50 U degludec/1.8 mg liraglutide · 26 weeksAs given in this study (human).
Source sentences
Summary
No unexpected safety signals were observed.
1 context sentence(design, population, supporting numbers)
Summary · context
In DUAL II China, a randomized, double-blinded, multicentre, treat-to-target trial, Chinese adults with T2D and HbA1c of 7.5% or more on basal insulin and metformin, with or without other oral antidiabetic drugs (OADs), were randomized 2:1 to 26 weeks of treatment with either IDegLira (max. dose 50…
Report a problemFND-3438741106

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.